Annotation Detail
Information
- Associated Genes
- PIK3CA
- Associated Variants
-
PIK3CA MUTATION
PIK3CA MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between PIK3CA mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 83 had wildtype PIK3CA and 14 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6300
- Gene URL
- https://civic.genome.wustl.edu/links/genes/37
- Variant URL
- https://civic.genome.wustl.edu/links/variants/311
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Does Not Support
- Drug
- Bevacizumab
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 19603024
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bevacizumab | Resitance or Non-Reponse | false |